Nurix Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics Depreciation & Amortization Growth & History (NRIX)
Nurix Therapeutics's depreciation and amortization was $8.7M for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | $8.7M | −$578,000 | −6.20% |
| 2024 | 2024-11-30 | $9.3M | $1.8M | +23.70% |
| 2023 | 2023-11-30 | $7.5M | $2.2M | +40.83% |
| 2022 | 2022-11-30 | $5.3M | $2.6M | +91.72% |
| 2021 | 2021-11-30 | $2.8M | $610,000 | +27.98% |
| 2020 | 2020-11-30 | $2.2M | −$174,000 | −7.39% |
| 2019 | 2019-11-30 | $2.4M | — | — |
Nurix Therapeutics quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $2.3M | $13,000 | +0.58% |
| Q1 2026 | 2026-02-28 | $2.2M | −$154,000 | −6.55% |
| Q4 2025 | 2025-11-30 | $4.6M | — | — |
| Q3 2025 | 2025-08-31 | $2.0M | −$366,000 | −15.29% |
| Q2 2025 | 2025-05-31 | $2.2M | −$88,000 | −3.78% |
| Q1 2025 | 2025-02-28 | $2.4M | $305,000 | +14.91% |
| Q3 2024 | 2024-08-31 | $2.4M | $443,000 | +22.71% |
| Q2 2024 | 2024-05-31 | $2.3M | $434,000 | +22.89% |
| Q1 2024 | 2024-02-29 | $2.0M | $293,000 | +16.72% |
| Q3 2023 | 2023-08-31 | $2.0M | $451,000 | +30.07% |
| Q2 2023 | 2023-05-31 | $1.9M | $596,000 | +45.85% |
| Q1 2023 | 2023-02-28 | $1.8M | $761,000 | +76.79% |
| Q3 2022 | 2022-08-31 | $1.5M | $800,000 | +114.29% |
| Q2 2022 | 2022-05-31 | $1.3M | $700,000 | +116.67% |
| Q1 2022 | 2022-02-28 | $991,000 | $348,000 | +54.12% |
| Q3 2021 | 2021-08-31 | $700,000 | $100,000 | +16.67% |
| Q2 2021 | 2021-05-31 | $600,000 | $100,000 | +20.00% |
| Q1 2021 | 2021-02-28 | $643,000 | $152,000 | +30.96% |
| Q3 2020 | 2020-08-31 | $600,000 | $0 | 0.00% |
| Q2 2020 | 2020-05-31 | $500,000 | — | — |
| Q1 2020 | 2020-02-29 | $491,000 | — | — |
| Q3 2019 | 2019-08-31 | $600,000 | — | — |
Nurix Therapeutics depreciation and amortization trends
Over the last five fiscal years, Nurix Therapeutics's depreciation and amortization increased from $2.2M to $8.7M, a change of $6.6M. The latest reported quarter, Q2 2026, shows $2.3M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗